Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

被引：11

作者：

Al-Batran, Salah-Eddin ^{[1
,3
]}

Hofheinz, Ralf-Dieter ^{[2
]}

Reichart, Alexander ^{[1
,3
]}

Pauligk, Claudia ^{[3
]}

Schoenherr, Caroline ^{[3
]}

Schlag, Rudolf ^{[4
]}

Siegler, Gabriele ^{[5
]}

Doerfel, Steffen ^{[6
]}

Koenigsmann, Michael ^{[7
]}

Zahn, Mark-Oliver ^{[8
]}

Schubert, Joerg ^{[9
]}

Aldaoud, Ali ^{[10
]}

Hoeffkes, Heinz-Gert ^{[11
,12
]}

Schulz, Holger ^{[13
]}

Hahn, Lars ^{[14
]}

Uhlig, Jens ^{[15
]}

Blau, Wolfgang ^{[16
]}

Stauch, Martina ^{[17
]}

Weniger, Joerg ^{[18
]}

Wolf, Martin ^{[19
]}

Jacobasch, Lutz ^{[20
]}

Bildat, Stephan ^{[21
,22
]}

Wehmeyer, Juergen ^{[23
]}

Homann, Nils ^{[24
]}

Trojan, Joerg ^{[25
]}

Waidmann, Oliver ^{[25
]}

Fietz, Thomas ^{[26
]}

Feustel, Hans-Peter ^{[27
]}

Groschek, Matthias ^{[28
]}

Wierecky, Jan ^{[29
]}

Waibel, Karin ^{[30
]}

Mahlmann, Stefan ^{[31
]}

Schwindel, Uwe ^{[32
]}

Peters, Uwe ^{[33
]}

Schuch, Gunter ^{[34
]}

Pink, Daniel ^{[35
,36
]}

Eschenburg, Henning ^{[37
]}

Woerns, Marcus-A. ^{[38
]}

Harich, Hans-Detlev ^{[39
]}

von Weikersthal, Ludwig Fischer ^{[40
]}

Daessler, Klaus-Ulrich ^{[41
]}

Behringer, Dirk M. ^{[42
]}

Messmann, Helmut ^{[43
]}

Kretzschmar, Albrecht ^{[44
]}

Gallmeier, Eike ^{[45
]}

Forstbauer, Helmut ^{[46
]}

Kunzmann, Volker ^{[47
]}

Papke, Jens ^{[48
]}

Buechner-Steudel, Petra ^{[49
]}

Vehling-Kaiser, Ursula ^{[50
]}

机构：

[1] UCT Univ Canc Ctr, Krankenhaus Nordwest, Frankfurt, Germany

[2] Univ Med Mannheim, Interdisziplinares Tumorzentrum, Mannheim, Germany

[3] Krankenhaus NW Frankfurt, Inst Klin Krebsforsch IKF GmbH, Frankfurt, Germany

[4] Gemeinschaftspraxis Schlag Schottker, Wurzburg, Germany

[5] Klinikum Nurnberg PMU, Nurnberg, Germany

[6] Onkozentrum Dresden, Dresden, Germany

[7] MediProjekt GbR, Hannover, Germany

[8] MVZ Onkol Kooperat Harz, Goslar, Germany

[9] Elblandklinikum Riesa, Riesa, Germany

[10] HELIOS Pk Klinikum, Pankreaszentrum Leipzig, Leipzig, Germany

[11] Univ Med Marburg, Klinikum Fulda, Fulda, Germany

[12] MVZ Osthessen GmbH, Fulda, Germany

[13] Pioh Frechen Koln Praxis Internist Onkol & Hamato, Frechen, Germany

[14] Dokusan Gesell Med Studien GmbH & Co KG, Herne, Germany

[15] Hamatol Onkol Schwerpunktpraxis, Naunhof, Germany

[16] Univ Klinikum Giessen & Marburg, Med Klin 4 5, Giessen, Germany

[17] Schwerpunktpraxis Hamatol Onkol, Kronach, Germany

[18] Gemeinschaftspraxis Hamatol & Onkol Dres Wenige B, Erfurt, Germany

[19] Klinikum Kassel GmbH, Klin Hamatol & Onkol, Kassel, Germany

[20] Onkol Gemeinschaftspraxis Dr Med Lutz Jacobasch, Dresden, Germany

[21] Klinikum Herford, Med Klin 2, Herford, Germany

[22] Onkol Zentrum, MVZ Onkol, Herford, Germany

[23] Gemeinschaftspraxis Hamatol & Onkol, Munster, Germany

[24] Klinikum Wolfsburg, Med Klin 2, Wolfsburg, Germany

[25] Klinikum JW Goethe Univ Frankfurt, Frankfurt, Germany

[26] Schwerpunktpraxis Hamatol, Onkol & Gastroenterol Dres Banhardt Fietz Hertkor, Singen, Germany

[27] Onkol Schwerpunktpraxis Speyer, Speyer, Germany

[28] Clin Res Stolberg GmbH, Stolberg, Germany

[29] Schwerpunkt Hamatol Onkol & Palliativmed, Uberortliche Gemeinschaftspraxis, Hamburg, Germany

[30] Medius Kliniken gGmbH, Medius Klin Ostfildern Ruit, Ostfildern Ruit, Germany

[31] Westpfalz Klinikum GmbH, Kaiserslautern, Germany

[32] GPR Gesundheits & Pflegezentrum gGmbH, Med Klin 1, Russelsheim, Germany

[33] Ambulantes Tumorzentrum Spandau Dres Peters & Sae, Berlin, Germany

[34] Hamatol Onkol Praxis Altona HOPA, Hamburg, Germany

[35] Ernst Moritz Arndt Univ Greifswald, Klin & Poliklin Innere Med C, Hamatol & Onkol, Transplantationszentrum,Palliativmed, Greifswald, Germany

[36] HELIOS Klinikum Bad Saarow, Sarkomzentrum Berlin Brandenburg, Klin Hamatol Onkol & Palliativmed, Brandenburg, Germany

[37] Internist Gemeinschaftspraxis Dres, Gustrow, Germany

[38] Univ Med Mainz, Med Klin & Poliklin 1, Mainz, Germany

[39] Onkol Hof MVZ Dres Kasper Harich, Hof, Germany

[40] Gesundheitszentrum St Marien GmbH, Praxis Hamatol & Internist Onkol, Amberg, Germany

[41] Praxis Dipl Med Klaus Ulrich Dassler, Freital, Germany

[42] Augusta Kranken Anstalt gGmbH, Bochum, Germany

[43] Univ Klinikum Augsburg, Med Klin 3, Augsburg, Germany

[44] MVZ Mitte Onkol Schwerpunktpraxis, Leipzig, Germany

[45] Univ Klinikum Giessen & Marburg GmbH, Klin Innere Med, Marburg, Germany

[46] GOSPL Gesell Onkol Studien, Troisdorf, Germany

[47] Univ Klin Wurzburg, Zentrum Innere Med, Med Klin & Poliklin 2, Wurzburg, Germany

[48] Praxis Prof Dr Med Jens Papke, Neustadt, Germany

[49] Univ Klinikum Halle Saale, Klin & Poliklin Innere Med 1, Halle, Germany

[50] VK&K Studien GbR, Landshut, Germany

来源：

INTERNATIONAL JOURNAL OF CANCER | 2021年 / 148卷 / 06期

关键词：

chemotherapy; pancreatic cancer; PARAGON; QOLIXANE; quality of life; registry; PLUS GEMCITABINE; SURVIVAL; FOLFIRINOX; IMPACT; THERAPY; MPACT;

D O I：

10.1002/ijc.33336

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Few data exist on health-related quality of life (QoL) in patients with metastatic pancreatic cancer (mPC) receiving first-line chemotherapy (Awad L ZE, Mesbah M Boston, MA. Applying survival data methodology to analyze quality of life data, in Mesbah M, Cole BF, Ting Lee M-L (eds): Statistical Methods for Quality of Life Studies: Design, Measurements and Analysis. Kluwer Academic Publishers 2002). The QOLIXANE study is a prospective, noninterventional, multicenter substudy of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer (PARAGON) registry, which evaluated QoL in patients with mPC receiving first-line gemcitabine and nab-paclitaxel chemotherapy in real-life setting. QoL was prospectively measured via EORTC QLQ-C30 questionnaires at baseline and every month thereafter. Therapy and efficacy parameters were prospectively collected. Main objectives were the rate of patients without deterioration of Global Health Status/QoL (GHS/QoL) at 3 and 6 months. Six hundred patients were enrolled in 95 German study sites. Median progression-free survival was 5.9 months (95% confidence interval [CI], 5.2-6.3). Median overall survival (OS) was 8.9 months (95% CI, 7.9-10.2), while median time to deterioration of GHS/QoL was 4.7 months (95% CI, 4.0-5.6). With a baseline GHS/QoL score of 46 (SD, 22.8), baseline QoL of the patients was severely impaired, in most cases due to loss in role functioning and fatigue. In the Kaplan-Meier analysis, 61% and 41% of patients had maintained GHS/QoL after 3 and 6 months, respectively. However, in the QoL response analysis, 35% and 19% of patients had maintained (improved or stable) GHS/QoL after 3 and 6 months, respectively, while 14% and 9% had deteriorated GHS/QoL with the remaining patients being nonevaluable. In the Cox regression analysis, GHS/QoL scores strongly predicted survival with a hazard ratio of 0.86 (P < .0001). Patients with mPC have poor QoL at baseline that deteriorates within a median of 4.7 months. Treatment with gemcitabine and nab-paclitaxel is associated with maintained QoL in relevant proportions of patients. However, overall, results remain poor, reflecting the aggressive nature of the disease.

引用

页码：1478 / 1488

页数：11

共 50 条

[31] Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2
Munoz Martin, Andres J.
Garcia Alfonso, Pilar
Ruperez, Ana B.
Martin Jimenez, Miguel
ONCOLOGY LETTERS, 2016, 12 (01) : 727 - 730
[32] Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
Arciero, Vanessa
Luo, Jin
Parmar, Ambica
Dai, Wei Fang
Beca, Jaclyn M.
Raphael, Michael J.
Isaranuwatchai, Wanrudee
Habbous, Steven
Tadrous, Mina
Earle, Craig C.
Biagi, Jim J.
Mittmann, Nicole
Arias, Jessica
Gavura, Scott
Chan, Kelvin K. W.
JNCI CANCER SPECTRUM, 2022, 6 (04)
[33] ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer
A. Koumarianou
P. Makrantonakis
F. Zagouri
C. Papadimitriou
A. Christopoulou
E. Samantas
C. Christodoulou
A. Psyrri
D. Bafaloukos
G. Aravantinos
P. Papakotoulas
S. Baka
C. Andreadis
A. Alexopoulos
I. Bompolaki
Κ. Kampoli
S. Liori
K. Karvounis
A. Ardavanis
Breast Cancer Research and Treatment, 2020, 182 : 85 - 96
[34] ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer
Koumarianou, A.
Makrantonakis, P.
Zagouri, F.
Papadimitriou, C.
Christopoulou, A.
Samantas, E.
Christodoulou, C.
Psyrri, A.
Bafaloukos, D.
Aravantinos, G.
Papakotoulas, P.
Baka, S.
Andreadis, C.
Alexopoulos, A.
Bompolaki, I
Kampoli, K.
Liori, S.
Karvounis, K.
Ardavanis, A.
BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 85 - 96
[35] nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
Yardley, D. A.
Coleman, R.
Conte, P.
Cortes, J.
Brufsky, A.
Shtivelband, M.
Young, R.
Bengala, C.
Ali, H.
Eakel, J.
Schneeweiss, A.
de la Cruz-Merino, L.
Wilks, S.
O'Shaughnessy, J.
Gluck, S.
Li, H.
Miller, J.
Barton, D.
Harbeck, N.
ANNALS OF ONCOLOGY, 2018, 29 (08) : 1763 - 1770
[36] The Appropriate First-Line Chemotherapy Regimen for Incurable Pancreatic Cancer in Clinical Practice: A Consideration of Patients' Overall Survival and Quality of Life
Murakawa, Yasuko
Ootsuka, Kazunori
Abue, Makoto
JOURNAL OF PANCREATIC CANCER, 2021, 7 (01) : 48 - 56
[37] The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
Schuurhuizen, Claudia S. E. W.
Verheul, Henk M. W.
Braamse, Annemarie M. J.
Buffart, Laurien M.
Bloemendal, Haiko J.
Dekker, Joost
Konings, Inge R. H. M.
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3015 - 3021
[38] The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study
Riedl, Jakob Michael
Posch, Florian
Prager, Gerald
Eisterer, Wolfgang
Oehler, Leopold
Sliwa, Thamer
Wilthoner, Klaus
Petzer, Andreas
Pichler, Petra
Hubmann, Eva
Winder, Thomas
Burgstaller, Sonja
Korger, Markus
Andel, Johannes
Greil, Richard
Neumann, Hans-Joerg
Pecherstorfer, Martin
Philipp-Abbrederis, Kathrin
Djanani, Angela
Gruenberger, Birgit
Laengle, Friedrich
Woell, Ewald
Gerger, Armin
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
[39] Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel
Yamai, Takuo
Ikezawa, Kenji
Hiraga, Erika
Kawamoto, Yasuharu
Hirao, Takeru
Higashi, Sena
Daiku, Kazuma
Maeda, Shingo
Abe, Yutaro
Urabe, Makiko
Kai, Yugo
Takada, Ryoji
Nakabori, Tasuku
Fukutake, Nobuyasu
Uehara, Hiroyuki
Fujita, Masashi
Ohkawa, Kazuyoshi
PLOS ONE, 2022, 17 (03):
[40] Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial
Anwar, Sidra
Tan, Wei
Yu, Jinhee
Hutson, Alan
Javle, Milind
Iyer, Renuka
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 5 (06) : 433 - 439

← 1 2 3 4 5 →